Theravance Biopharma to Participate in an Upcoming Investor Conference
Rhea-AI Summary
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).
Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Positive
- None.
Negative
- None.
Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302368408.html
SOURCE Theravance Biopharma, Inc.
FAQ
When is Theravance Biopharma (TBPH) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch TBPH's Oppenheimer Conference presentation?
How long will TBPH's Oppenheimer Conference presentation replay be available?
What time is TBPH's Oppenheimer presentation in PST and GMT?
